JP2017036288A5 - - Google Patents

Download PDF

Info

Publication number
JP2017036288A5
JP2017036288A5 JP2016175431A JP2016175431A JP2017036288A5 JP 2017036288 A5 JP2017036288 A5 JP 2017036288A5 JP 2016175431 A JP2016175431 A JP 2016175431A JP 2016175431 A JP2016175431 A JP 2016175431A JP 2017036288 A5 JP2017036288 A5 JP 2017036288A5
Authority
JP
Japan
Prior art keywords
inhibitor
subject
administered
use according
jak
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016175431A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017036288A (ja
JP6375345B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2017036288A publication Critical patent/JP2017036288A/ja
Publication of JP2017036288A5 publication Critical patent/JP2017036288A5/ja
Application granted granted Critical
Publication of JP6375345B2 publication Critical patent/JP6375345B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016175431A 2011-04-28 2016-09-08 Ｈｓｐ９０併用療法 Expired - Fee Related JP6375345B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161480198P 2011-04-28 2011-04-28
US61/480,198 2011-04-28

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2014508165A Division JP6363502B2 (ja) 2011-04-28 2012-04-27 Ｈｓｐ９０併用療法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018106047A Division JP2018153194A (ja) 2011-04-28 2018-06-01 Ｈｓｐ９０併用療法

Publications (3)

Publication Number Publication Date
JP2017036288A JP2017036288A (ja) 2017-02-16
JP2017036288A5 true JP2017036288A5 (enExample) 2017-07-13
JP6375345B2 JP6375345B2 (ja) 2018-08-15

Family

ID=47073116

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2014508165A Expired - Fee Related JP6363502B2 (ja) 2011-04-28 2012-04-27 Ｈｓｐ９０併用療法
JP2016175431A Expired - Fee Related JP6375345B2 (ja) 2011-04-28 2016-09-08 Ｈｓｐ９０併用療法
JP2018106047A Withdrawn JP2018153194A (ja) 2011-04-28 2018-06-01 Ｈｓｐ９０併用療法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2014508165A Expired - Fee Related JP6363502B2 (ja) 2011-04-28 2012-04-27 Ｈｓｐ９０併用療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018106047A Withdrawn JP2018153194A (ja) 2011-04-28 2018-06-01 Ｈｓｐ９０併用療法

Country Status (12)

Country Link
US (2) US20140315929A1 (enExample)
EP (1) EP2701747A4 (enExample)
JP (3) JP6363502B2 (enExample)
KR (2) KR102027448B1 (enExample)
CN (2) CN109498812A (enExample)
AU (3) AU2012249322B2 (enExample)
BR (1) BR112013027448A2 (enExample)
CA (1) CA2833390A1 (enExample)
EA (1) EA201391587A1 (enExample)
MX (1) MX2013012183A (enExample)
NZ (1) NZ618062A (enExample)
WO (1) WO2012149493A2 (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2841069C (en) 2011-07-08 2021-11-23 Sloan-Kettering Institute For Cancer Research Uses of labeled hsp90 inhibitors
US20140079636A1 (en) * 2012-04-16 2014-03-20 Dinesh U. Chimmanamada Targeted therapeutics
US8993555B2 (en) 2012-12-21 2015-03-31 Epizyme, Inc. PRMT5 inhibitors and uses thereof
WO2015089402A1 (en) * 2013-12-12 2015-06-18 The University Of Chicago Methods and compositions related to hsp90 inhibitors and breast cancer
AU2014386214B2 (en) 2013-12-23 2020-05-21 Memorial Sloan-Kettering Cancer Center Methods and reagents for radiolabeling
WO2015168599A1 (en) * 2014-05-02 2015-11-05 The Wistar Institute Of Anatomy And Biology Combination therapies targeting mitochondria for cancer therapy
BR112017005313A2 (pt) 2014-09-17 2017-12-05 Memorial Sloan Kettering Cancer Center formação de imagem e terapia para inflamação e infecção direcionadas por hsp90
US9710606B2 (en) 2014-10-21 2017-07-18 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for neurological health issues
US10325685B2 (en) 2014-10-21 2019-06-18 uBiome, Inc. Method and system for characterizing diet-related conditions
US10793907B2 (en) 2014-10-21 2020-10-06 Psomagen, Inc. Method and system for microbiome-derived diagnostics and therapeutics for endocrine system conditions
US10346592B2 (en) 2014-10-21 2019-07-09 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for neurological health issues
US10381112B2 (en) 2014-10-21 2019-08-13 uBiome, Inc. Method and system for characterizing allergy-related conditions associated with microorganisms
US10409955B2 (en) 2014-10-21 2019-09-10 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for locomotor system conditions
US9760676B2 (en) 2014-10-21 2017-09-12 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for endocrine system conditions
US11783914B2 (en) 2014-10-21 2023-10-10 Psomagen, Inc. Method and system for panel characterizations
US10073952B2 (en) 2014-10-21 2018-09-11 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for autoimmune system conditions
US10388407B2 (en) 2014-10-21 2019-08-20 uBiome, Inc. Method and system for characterizing a headache-related condition
US10777320B2 (en) 2014-10-21 2020-09-15 Psomagen, Inc. Method and system for microbiome-derived diagnostics and therapeutics for mental health associated conditions
US10169541B2 (en) 2014-10-21 2019-01-01 uBiome, Inc. Method and systems for characterizing skin related conditions
US9758839B2 (en) 2014-10-21 2017-09-12 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for conditions associated with microbiome functional features
US10265009B2 (en) 2014-10-21 2019-04-23 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for conditions associated with microbiome taxonomic features
US10410749B2 (en) 2014-10-21 2019-09-10 uBiome, Inc. Method and system for microbiome-derived characterization, diagnostics and therapeutics for cutaneous conditions
EP3209803A4 (en) 2014-10-21 2018-06-13 Ubiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics
US9754080B2 (en) 2014-10-21 2017-09-05 uBiome, Inc. Method and system for microbiome-derived characterization, diagnostics and therapeutics for cardiovascular disease conditions
US10357157B2 (en) 2014-10-21 2019-07-23 uBiome, Inc. Method and system for microbiome-derived characterization, diagnostics and therapeutics for conditions associated with functional features
US10789334B2 (en) 2014-10-21 2020-09-29 Psomagen, Inc. Method and system for microbial pharmacogenomics
US10311973B2 (en) 2014-10-21 2019-06-04 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for autoimmune system conditions
US10366793B2 (en) 2014-10-21 2019-07-30 uBiome, Inc. Method and system for characterizing microorganism-related conditions
US10395777B2 (en) 2014-10-21 2019-08-27 uBiome, Inc. Method and system for characterizing microorganism-associated sleep-related conditions
WO2016168344A1 (en) * 2015-04-13 2016-10-20 uBiome, Inc. Method and system for microbiome-derived characterization, diaganostics and therapeutics for conditions associated with functional features
US10246753B2 (en) 2015-04-13 2019-04-02 uBiome, Inc. Method and system for characterizing mouth-associated conditions
CN106265660B (zh) * 2015-05-21 2019-08-02 中国科学院合肥物质科学研究院 A674563在携带flt3突变型基因的急性白血病中的用途
CN106349180B (zh) * 2015-07-14 2020-05-19 上海翰森生物医药科技有限公司 4,5-二苯基异噁唑衍生物及其制备方法和应用
WO2018027084A2 (en) * 2016-08-03 2018-02-08 Remd Biotherapeutics, Inc. Combination of glucagon receptor antagonists and pi3k pathway inhibitors for the treatment of cancer
TW201840337A (zh) 2017-02-03 2018-11-16 美商藍治療公司 使用ｈｓｐ９０抑制劑治療癌症的方法
JP2020524156A (ja) 2017-06-20 2020-08-13 マドリガル ファーマシューティカルズ インコーポレイテッドＭａｄｒｉｇａｌ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 標的治療薬を含む併用療法
JP2020524154A (ja) 2017-06-20 2020-08-13 マドリガル ファーマシューティカルズ インコーポレイテッドＭａｄｒｉｇａｌ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 標的治療薬
JP7558167B2 (ja) 2018-12-03 2024-09-30 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム オリゴベンズアミド類似体およびがん処置におけるそれらの使用
CN109554343B (zh) * 2018-12-29 2022-04-19 吉林大学 一种适于神经元粘附与存活的涂层材料及制备方法
WO2020206608A1 (en) 2019-04-09 2020-10-15 Ranok Therapeutics (Hangzhou) Co., Ltd. Methods and compositions for targeted protein degradation
CN111467472B (zh) * 2020-04-21 2020-12-25 南京中医药大学 一种靶向肿瘤相关巨噬细胞的免疫调节微球制剂及其制备方法与应用
WO2021252490A2 (en) * 2020-06-11 2021-12-16 The Children's Medical Center Corporation Use of heat shock protein inhibitors for the treatment of neurodevelopmental disorders
KR20240073137A (ko) 2020-09-09 2024-05-24 소셜 프로핏 네트워크 미토콘드리아에 비오틴의 전달을 위한 방법 및 조성물
IL302081A (en) * 2020-10-14 2023-06-01 Ranok Therapeutics Hangzhou Co Ltd Methods and compositions for targeted protein degradation

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303652B1 (en) * 1998-08-21 2001-10-16 Hughes Institute BTK inhibitors and methods for their identification and use
US20070105874A1 (en) 2005-09-23 2007-05-10 Conforma Therapeutics Corporation Anti-Tumor Methods Using Multi Drug Resistance Independent Synthetic HSP90 Inhibitors
JP5721949B2 (ja) * 2006-10-12 2015-05-20 アステックス、セラピューティックス、リミテッドＡｓｔｅｘ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ 複合薬剤
EP2491923A3 (en) * 2007-02-15 2012-12-26 Novartis AG Combinations of therapeutic agents for treating cancer
WO2008114812A1 (ja) * 2007-03-19 2008-09-25 Kyowa Hakko Kirin Co., Ltd. Jak阻害剤
KR20140098185A (ko) * 2007-07-30 2014-08-07 아디아 바이오사이언스즈 인크. 다형체를 포함하는, ｍｅｋ의 억제제로서의 ｎ-(아릴아미노) 술폰아미드의 유도체 및 조성물, 사용 방법 및 이의 제조 방법
US20100310563A1 (en) * 2007-11-30 2010-12-09 Bumm Thomas G P Methods for treating induced cellular proliferative disorders
WO2010006072A2 (en) * 2008-07-08 2010-01-14 The Regents Of The University Of California Mtor modulators and uses thereof
EP2321645A1 (en) * 2008-08-18 2011-05-18 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Susceptibility to hsp90-inhibitors
ES2621141T3 (es) * 2008-11-28 2017-07-03 Novartis Ag Combinación farmacéutica que comprende un inhibidor de Hsp 90 y un inhibidor de mTOR
US8669289B2 (en) 2009-04-24 2014-03-11 The Jackson Laboratory Methods and compositions relating to hematologic malignancies
ES2632220T3 (es) * 2009-06-15 2017-09-11 Rigel Pharmaceuticals, Inc. Inhibidores de moléculas pequeñas de tirosina cinasa del bazo (SYK)
NZ598262A (en) * 2009-08-17 2014-05-30 Sloan Kettering Inst Cancer Heat shock protein binding compounds, compositions, and methods for making and using same
CN102713606A (zh) * 2009-11-13 2012-10-03 无限制药股份有限公司 用于鉴定、评估、预防和治疗癌症的组合物、试剂盒和方法
NZ772688A (en) * 2010-06-03 2022-09-30 Pharmacyclics Llc The use of inhibitors of bruton’s tyrosine kinase (btk)
US20140315943A1 (en) * 2011-05-24 2014-10-23 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with mtor/p13k inhibitors

Similar Documents

Publication Publication Date Title
MX2024010140A (es) Nuevos metodos.
JP2023506532A5 (enExample)
FI3265084T3 (fi) Brutonin tyrosiinikinaasin estäjän lääkeformulaatioita
JP2016163571A5 (enExample)
JP2017057230A5 (enExample)
NO20092585L (no) Forbindelser og farmasoytiske sammensetninger for behandling av virale infeksjoner
WO2020115555A3 (en) Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia
JP2014530874A5 (enExample)
ME02400B (me) Policiklična karbamoilpiridonska jedinjenja i njihova farmaceutska upotreba
ES2527544T1 (es) Tratamiento mono (PSI-7977) o de combinación con AAD para su uso en el tratamiento del VHC
IL295418B1 (en) Beta-d-2'-deoxy-2' alpha-fluoro-2'-bata-c-modified-2-different-n6-purine modified nucleotides for the treatment of hepatitis c virus
JP2006508953A5 (enExample)
CN110891953A (zh) 吡咯并三嗪类衍生物、其制备方法及其用途
AR062453A1 (es) Metodo de terapia combinada para el tratamiento de la infeccion por el virus de la hepatitis c y composiciones farmaceuticas para usar en dicha terapia
JP2020529995A5 (enExample)
JP2021535107A5 (enExample)
FI3661510T3 (fi) Menetelmiä käyttäytymismuutosten hoitamiseksi
JP2022532038A5 (enExample)
JP2019530711A5 (enExample)
WO2023043830A1 (en) Combination therapies to treat viral infections
FI3600276T3 (fi) Betahistiini tai sen farmaseuttisesti hyväksyttävä suola ja monoamiinioksidaasin inhibiittori käytettäväksi yhden tai useamman huimausoireen hoitamisessa tai ehkäisemisessä kohteessa
JP2023531930A5 (enExample)
CN109689657A (zh) 氘代3-(4,5-取代氨基嘧啶)苯基衍生物及其应用
JP2019520407A5 (enExample)
HRP20110365T1 (hr) Kombinacija azd2171 i pemetrekseda